Therefore, SRPIN340 (an inhibitor of both SRPK1 and SRPK2) was selected based on strong in vivo evidence of its melanoma-suppressive effects,16 while SPHINX31 (an SRPK1-specific inhibitor) was chosen due to the increased count of SRPK1 transcripts (Figure 1A) and its clinical relevance to melanoma patient survival (Figure 1B-C). This evidence concerns the gene SRPK2 and melanoma.